In the synovial tissue of RA, p38 is highly expressed and activated, and the commonly used p38 MAPK inhibitor SB203580 reduces the production of pro-inflammatory cytokines by monocytes/macrophages, neutrophils and T lymphocytes 109. Here, MAPK14 is linked to rheumatoid arthritis.